Ipamorelin: A Guide to This Growth Hormone Secretagogue

Reviewed by Dr. James Harlow, MD, Sports Medicine
Topics: GH Peptides
Ipamorelin: A Guide to This Growth Hormone Secretagogue
⚠️ Research Disclaimer: This content is for educational purposes only. All compounds discussed are research peptides. Consult a qualified healthcare professional before considering any protocol.

Introduction to Ipamorelin

Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective ghrelin receptor agonist. It belongs to the growth hormone releasing peptide (GHRP) family but is noted for its high selectivity — it stimulates GH release without significantly raising cortisol, prolactin, or ACTH levels, which differentiates it from older GHRPs like GHRP-6.

Mechanism of Action

Ipamorelin binds to the ghrelin receptor (GHS-R1a) in the pituitary gland, stimulating growth hormone release in a pulsatile fashion that closely mimics natural GH secretion patterns. Its selectivity is attributed to its structural differences from other GHRPs that non-selectively activate multiple pathways.

Selectivity Profile

In animal studies comparing Ipamorelin to GHRP-2 and GHRP-6:

  • Ipamorelin produced comparable GH release
  • Minimal cortisol or ACTH elevation (unlike GHRP-6)
  • No significant prolactin elevation
  • No notable effect on appetite (unlike GHRP-6 which strongly increases appetite via ghrelin)

Research Applications

Ipamorelin is often studied in combination with CJC-1295, a GHRH analogue, as the two peptides work synergistically — CJC-1295 extends the GH release window while Ipamorelin amplifies the pulse.

Important Disclaimer

Ipamorelin is a research peptide. This information is for educational purposes only and does not constitute medical advice.

Sources & Further Reading

Peer-reviewed clinical trial data and research publications underpinning this article. See our full research library.

  1. Raun K, Hansen BS, Johansen NL, et al. (1998). Ipamorelin, the First Selective Growth Hormone Secretagogue. European Journal of Endocrinology, 139:552–561. Animal + In Vitro